Alzheimer's Disease Clinical Trial
Official title:
Systematic Characterization of the Cellular Proteome From Human Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular
neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion
cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is
known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier
studies the investigators could demonstrate that the process of apoptosis is reflected in
circulating leukocytes by different parameters, like differential mRNA expression and an
increased fragmentation of the DNA. Such alterations point out a relationship between
cellular stress and apoptotic events.
Based on the results of mRNA-expression the investigators also expect alterations on the
protein level.
This study is, therefore, designed to characterize the proteome related to the proteins
involved in cell death related pathways.
Thus, the expression pattern of several proteins in leukocytes from patients with primary
open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass
spectrometry. These samples will be compared with samples from healthy controls. In
addition, they will also be compared with samples from patients with Alzheimer's disease.
Since glaucoma is a neurodegenerative disease, these patients will be included as positive
controls in this study.
Hypothesis:
Differences in the proteome concerning cell death pathways of glaucoma patients correspond
to the differences in the mRNA expression of these patients.
Specific aims:
Characterization of the cellular proteome from human leukocytes of glaucoma patients
compared to healthy controls and patients with Alzheimer's disease.
Background:
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular
neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion
cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is
known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier
studies we could demonstrate that this cell death is reflected in circulating leukocytes by
different parameters, like differential mRNA expression, and an increased fragmentation of
the DNA. The differences in mRNA expression indicate a close relationship to cellular stress
conditions and apoptotic events: increased mRNA expression was detected for p53, 20S
proteasome alpha subunit, ABC1 transporter, p21(WAF1/CIP1), 14-3-3 sigma factor, MMP-9 and
MMP-14, and TIMP-1.
Based on the assumption that glaucoma patients may differ on the level of their expression
for these mRNAs, we expect that similar differences should exist at the protein level.
This study is, therefore, designed to characterize the proteome related to the proteins
involved in cell death related pathways.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02094729 -
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
|
Phase 1 |